We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+55.36%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$750M
AUM Growth
+$187M
Cap. Flow
+$114M
Cap. Flow %
15.17%
Top 10 Hldgs %
73.32%
Holding
52
New
16
Increased
12
Reduced
5
Closed
13

Top Buys

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$28.5M
2
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$28M
3
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$22M
4
ASND icon
Ascendis Pharma A/S
ASND
+$17.9M
5
KURA icon
Kura Oncology
KURA
+$16.3M

Top Sells

Rank Stock Value
1
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$29.5M
2
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$25.9M
3
EDIT icon
Editas Medicine
EDIT
+$12M
4
TTPH
Tetraphase Pharmaceuticals, Inc.
TTPH
+$4.52M
5
ACHN
Achillion Pharmaceuticals
ACHN
+$3.41M

Sector Composition

Rank Sector Weight
1 Healthcare 97.33%
2 Miscellaneous 2.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASMB icon
1
Assembly Biosciences
ASMB
$694M
$103M 13.7%
245,264
– –
KYNB
2
Kyntra Bio
KYNB
$32.5M
$93.4M 12.45%
69,427
+6,009
+9% +$6.33M
IRWD icon
3
Ironwood Pharmaceuticals
IRWD
$682M
$86.1M 11.47%
6,518,742
+2,036,902
+45% +$28M
ASND icon
4
Ascendis Pharma A/S
ASND
$16.3B
$76.4M 10.18%
2,107,600
+625,000
+42% +$17.9M
KURA icon
5
Kura Oncology
KURA
$1.13B
$56.3M 7.51%
3,766,852
+1,733,230
+85% +$16.3M
IMMU
6
DELISTED
Immunomedics Inc
IMMU
$40M 5.33%
+2,860,019
New +$28.5M
MYOK
7
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$29.6M 3.94%
+689,986
New +$22M
LKFT
8
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$24.5M 3.27%
240,776
-337,729
-58% -$29.5M
MRNS
9
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$21.3M 2.83%
+905,568
New +$10.2M
ATYR
10
aTyr Pharma
ATYR
$53M
$19.9M 2.65%
281,061
+117,300
+72% +$5.43M
FBRX
11
DELISTED
Forte Biosciences
FBRX
$18.7M 2.49%
4,006
– –
ARRY
12
DELISTED
Array Biopharma Inc
ARRY
$15.4M 2.05%
+1,250,000
New +$11.6M
CTMX icon
13
CytomX Therapeutics
CTMX
$699M
$15.1M 2.01%
829,771
+34,802
+4% +$543K
CRVS icon
14
Corvus Pharmaceuticals
CRVS
$1.19B
$14.5M 1.93%
908,525
+103,525
+13% +$1.43M
INDP icon
15
Indaptus Therapeutics
INDP
$152M
$13.4M 1.79%
+670
New +$9.66M
INSM icon
16
Insmed
INSM
$25.9B
$12.7M 1.69%
+405,400
New +$7.72M
WVE icon
17
Wave Life Sciences
WVE
$993M
$12.3M 1.64%
+564,248
New +$11.3M
CASC
18
DELISTED
Cascadian Therapeutics, Inc.
CASC
$12.3M 1.64%
3,000,000
– –
VRTX icon
19
CALL
Vertex Pharmaceuticals
VRTX
$137B
$10.3M 1.37%
67,600
+7,600
+13% +$1.14M
IRWD icon
20
CALL
Ironwood Pharmaceuticals
IRWD
$682M
$9.78M 1.3%
+740,280
New +$10.2M
OMER icon
21
Omeros
OMER
$1.35B
$9.73M 1.3%
+450,000
New +$9.53M
FATE icon
22
Fate Therapeutics
FATE
$291M
$8.96M 1.19%
2,262,678
-274,348
-11% -$933K
RGLS
23
DELISTED
Regulus Therapeutics
RGLS
$6.55M 0.87%
43,660
+12,750
+41% +$1.6M
DRNA
24
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$5.51M 0.73%
957,992
+190,000
+25% +$691K
TPST icon
25
Tempest Therapeutics
TPST
$17.5M
$4.99M 0.66%
1,201
– –
1
2 3

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q3 2017 Portfolio in Review

As of Q3 2017, EcoR1 Capital held 52 positions worth $750M, up 33% from $563M the previous quarter. Its ten largest holdings account for 73% of the portfolio.

EcoR1 Capital deployed $114M of net new capital in Q3 2017, opening 16 new positions and adding to 12 existing holdings. Its largest new stake was Immunomedics Inc: 2,860,019 shares worth $40M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 77% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Lakefront Biotherapeutics American Depositary Shares, an estimated $29.5M trimmed.

  • EcoR1 Capital's largest Q3 2017 buy was Immunomedics Inc: 2,860,019 shares worth $40M.
  • EcoR1 Capital added most to Ironwood Pharmaceuticals in Q3 2017, an estimated $28M increase.
  • EcoR1 Capital's biggest Q3 2017 reduction was Lakefront Biotherapeutics American Depositary Shares, cutting an estimated $29.5M.
  • EcoR1 Capital fully exited Editas Medicine in Q3 2017, selling an estimated $12M.
  • EcoR1 Capital's ten largest holdings make up 73% of its $750M portfolio in Q3 2017.
  • EcoR1 Capital opened 16 new positions and closed 13 in Q3 2017.
  • EcoR1 Capital's portfolio value rose 33% quarter-over-quarter to $750M.

Based on EcoR1 Capital's 13F filing for Q3 2017, filed 14 Nov 2017.